Our study shows that the combined silencing of the transcription factor FOSL-1 and the transcriptional coactivator YAP by siRNA-lipoplexes exerts a therapeutic effect against pancreatic cancer, achieving a reduction in tumor development and growth on both immunocompetent and immunocompromised allografted mouse models. Here, FOSL1 is linked to neoplasm.